Dabur Pharma Ltd has signed a supply and distribution agreement with Combino Pharm, a leading Spanish generic company, to distribute and market generic oncology products in the Spanish market, one of the fastest growing markets for generics in the world. According to IMS (March 2006) the value of the Spanish generic market during the year was approximately $750 million, with an annual growth rate of 25 per cent.
While Dabur Pharma will be responsible for registration and supply of products, Combino Pharm will handle the distribution, marketing and sales. Dabur Pharma, which already has approvals for three products in the UK, says that it expects to begin shipping the products to the Spanish market shortly and is awaiting mutual recognition procedure (MRP) approval for its products from the Spanish drugs regulatory authority.
"Both companies expect to benefit significantly from each other's strengths and the partnership should enable both to establish a significant presence in the Spanish oncology market," said Ajay Kumar Vij, CEO, Dabur Pharma.